Renal cell cancer (RCC) (epithelial carcinoma of the kidney) represents 2%–4% of newly diagnosed adult tumors. Over the past 2 decades, RCC has been better characterized clinically and molecularly. It is a heterogeneous disease, with multiple subtypes, each with characteristic histology, genetics, molecular profiles, and biologic behavior. Tremendous heterogeneity has been identified with many distinct subtypes characterized. There are clinical questions to be addressed at every stage of this disease, and new targets being identified for therapeutic development. The unique characteristics of the clinical presentations of RCC have led to both questions and opportunities for improvement in management. Advances in targeted drug development and understanding of immunologic control of RCC are leading to a number of new clinical trials and regimens for advanced disease, with the goal of achieving long-term disease-free survival, as has been achieved in a proportion of such patients historically. RCC management is a promising area of ongoing clinical investigation.
Get full access to this article
View all access options for this article.
References
1.
SiegelR, NaishadhamD, JemalA. Cancer statistics, 2013. CA Cancer J Clin2013;63:11–30.doi:10.3322/caac.21166
2.
EbleJN, SauterG, EpsteinJI, . World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press, 2004.
3.
SrigleyJR, DelahuntB, EbleJN, . The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol2013;37:1469–89.doi:10.1097/PAS.0b013e318299f2d1
4.
MochH, HumphreyPA, UlbrightTM, . WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer, 2016.
5.
MochH, CubillaAL, HumphreyPA, . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. Eur Urol2016;70:93–105.doi:10.1016/j.eururo.2016.02.029
6.
FrewIJ, MochH. A clearer view of the molecular complexity of clear cell renal cell carcinoma. Annu Rev Pathol2015;10:263–89.doi:10.1146/annurev-pathol-012414-040306
7.
ChevilleJC, LohseCM, ZinckeH, . Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol2003;27:612–24.doi:10.1097/00000478-200305000-00005
8.
TakahashiM, TehBT, KanayamaHO. Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. J Med Invest2006;53:9–19.doi:10.2152/jmi.53.9
9.
HaakeS, BrannonA, HackerK, . Use of meta-analysis of clear cell renal cell carcinoma gene expression to define a variant subgroup and identify gender issues on tumor biology. J Clin Oncol2013;30. abst 412.
10.
KaelinWG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res2007;13:680s–4.doi:10.1158/1078-0432.CCR-06-1865
11.
KaelinWJr. Molecular Biology of Kidney Cancer. In: LaraPJr, JonashE, eds. Kidney Cancer: principles and practice. Berlin: Springer, 2012:29–46.
12.
DelahuntB, EbleJN, McCredieMR, . Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol2001;32:590–5.doi:10.1053/hupa.2001.24984
13.
LinehanWM, SpellmanPT, RickettsCJ, . Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med2016;374:135–45.doi:10.1056/NEJMoa1505917
14.
ArganiP, LalP, HutchinsonB, . Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol2003;27:750–61.
15.
GellerJ, MullenE, KhannaG, . Epidemiology and characterization of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group Study AREN 03B2. Br J Urol Int2012;110:18–19. Abst 40.
16.
MaloufGG, CamparoP, OudardS, . Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol2010;21:1834–8.doi:10.1093/annonc/mdq029
17.
MaloufG, CamparoP, MolinieV, . TFE3 and TFEB renal cell carcinomas: Clinical features, biological behavior and prognostic features. J Urol2011;185:24–9.
18.
DavisCJ, MostofiFK, SesterhennIA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol1995;19:1–11.doi:10.1097/00000478-199501000-00001
19.
SwartzMA, KarthJ, SchneiderDT, . Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology2002;60:1083–9.doi:10.1016/S0090-4295(02)02154-4
TomlinsonIP, AlamNA, RowanAJ, . Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet2002;30:406–10.doi:10.1038/ng849
23.
MerinoMJ, Torres-CabalaC, PintoP, . The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol2007;31:1578–85.doi:10.1097/PAS.0b013e31804375b8
24.
GillAJ, HesO, PapathomasT, . Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol2014;38:1588–602.doi:10.1097/PAS.0000000000000292
25.
RickettsC, WoodwardER, KillickP, . Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst2008;100:1260–2.doi:10.1093/jnci/djn254
26.
ZhouM, YangXJ, LopezJI, . Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol2009;33:1840–9.doi:10.1097/PAS.0b013e3181be22d1
27.
AminMB, MacLennanGT, GuptaR, . Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol2009;33:384–92.doi:10.1097/PAS.0b013e3181872d3f
28.
YangXJ, ZhouM, HesO, . Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol2008;32:177–87.doi:10.1097/PAS.0b013e318150df1d
29.
AzoulayS, VieillefondA, ParafF, . Tubulocystic carcinoma of the kidney: a new entity among renal tumors. Virchows Arch2007;451:905–9.doi:10.1007/s00428-007-0483-7
30.
TickooSK, dePeralta-VenturinaMN, HarikLR, . Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol2006;30:141–53.
31.
RohanSM, XiaoY, LiangY, . Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol2011;24:1207–20.doi:10.1038/modpathol.2011.80
32.
ZhouH, ZhengS, TruongLD, . Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. Hum Pathol2014;45:59–64.doi:10.1016/j.humpath.2013.08.004
33.
WintersBR, GoreJL, HoltSK, . Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urol Oncol2015;33:505.e9–505.e13.doi:10.1016/j.urolonc.2015.07.017
34.
LatifF, ToryK, GnarraJ, . Identification of the von Hippel-Lindau disease tumor suppressor gene. Science1993;260:1317–20.doi:10.1126/science.8493574
LubenskyIA, SchmidtL, ZhuangZ, . Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol1999;155:517–26.doi:10.1016/S0002-9440(10)65147-4
37.
SchmidtLS, WarrenMB, NickersonML, . Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet2001;69:876–82.doi:10.1086/323744
38.
PavlovichCP, WaltherMM, EylerRA, . Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol2002;26:1542–52.doi:10.1097/00000478-200212000-00002
39.
HaasNB, NathansonKL. Hereditary renal cancer syndromes. Adv Chronic Kidney Dis2014211.
40.
LauWK, BluteML, WeaverAL, . Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc2000;75:1236–42.doi:10.4065/75.12.1236
41.
LeibovichBC, BluteML, ChevilleJC, . Neprhon sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol2000;163:730–6.
42.
ZiniL, PerrotteP, CapitanioU, . Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer2009;115:1465–71.doi:10.1002/cncr.24035
43.
LeeHJ, LissMA, DerweeshIH. Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors. Curr Opin Urol2014;24:448–52.doi:10.1097/MOU.0000000000000081
44.
KimSP, ThompsonRH, BoorjianSA, . Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol2012;188:51–7.doi:10.1016/j.juro.2012.03.006
45.
TanHJ, NortonEC, YeZ, . Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA2012;307:1629–35.doi:10.1001/jama.2012.475
46.
TouijerK, JacqminD, KavoussiLR, . The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol2010;57:214–22.doi:10.1016/j.eururo.2009.10.019
47.
WeightCJ, LieserG, LarsonBT, . Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol2010;58:293–8.doi:10.1016/j.eururo.2010.04.033
48.
FinelliA, IsmailaN, BroB, . Management of small renal masses: American Society of clinical oncology clinical practice guideline. J Clin Oncol2017;35:668–80.doi:10.1200/JCO.2016.69.9645
49.
JewettMA, RendonR, LacombeL, . Canadian guidelines for the management of small renal masses (SRM). Can Urol Assoc J2015;9:160–3.doi:10.5489/cuaj.2969
50.
MotzerRJ, JonaschE, AgarwalN, . Kidney Cancer, Version 2.2017. J Natl Compr Cancer Netw2017;15:804–34.
51.
HuangWC, AtoriaCL, BjurlinM, . Management of small kidney cancers in the new millennium: contemporary trends and outcomes in a population-based cohort. JAMA Surg2015;150:664–72.doi:10.1001/jamasurg.2015.0294
52.
AlmassiN, GillBC, RiniB, . Management of the small renal mass. Transl Androl Urol2017;6:923–30.doi:10.21037/tau.2017.07.11
53.
DechetCB, ZinckeH, SeboTJ, . Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol2003;169:71–4.doi:10.1016/S0022-5347(05)64038-4
JeonHG, SeoSI, JeongBC, . Percutaneous kidney biopsy for a small renal mass: a critical appraisal of results. J Urol2016;195:568–73.doi:10.1016/j.juro.2015.09.073
56.
HalversonSJ, KunjuLP, BhallaR, . Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol2013;189:441–6.doi:10.1016/j.juro.2012.09.032
57.
PrinceJ, BultmanE, HinshawL, . Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J Urol2015;193:1899–904.doi:10.1016/j.juro.2014.12.021
58.
FlaniganRC, SalmonSE, BlumensteinBA, . Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001;345:1655–9.doi:10.1056/NEJMoa003013
59.
MickischGH, GarinA, van PoppelH, . Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001;358:966–70.doi:10.1016/S0140-6736(01)06103-7
60.
ChoueiriTK, XieW, KollmannsbergerC, . The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol2011;185:60–6.doi:10.1016/j.juro.2010.09.012
61.
HengDY, WellsJC, RiniBI, . Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol2014;66:704–10.doi:10.1016/j.eururo.2014.05.034
62.
PetrelliF, CoinuA, VavassoriI, . Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer2016;14:465–72.doi:10.1016/j.clgc.2016.04.001
63.
HengDY, XieW, ReganMM, . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol2009;27:5794–9.doi:10.1200/JCO.2008.21.4809
64.
HengDY, XieW, ReganMM, . External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol2013;14:141–8.doi:10.1016/S1470-2045(12)70559-4
65.
AltAL, BoorjianSA, LohseCM, . Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer2011;117:2873–82.doi:10.1002/cncr.25836
66.
ThomasAZ, AdibiM, BorregalesLD, . Role of metastasectomy in metastatic renal cell carcinoma. Curr Opin Urol2015;25:381–9.doi:10.1097/MOU.0000000000000196
67.
BianchiM, SunM, JeldresC, . Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol2012;23:973–80.doi:10.1093/annonc/mdr362
68.
SantiniD, ProcopioG, PortaC, . Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. PLoS One2013;8:e83026.doi:10.1371/journal.pone.0083026
69.
GrünwaldV, EberhardtB, BexA, . An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol2018;15:511–21.doi:10.1038/s41585-018-0034-9
70.
NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. 2018.
71.
StenmanM, SinclairG, PaavolaP, . Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiother Oncol2018;127:501–6.doi:10.1016/j.radonc.2018.04.028
72.
MeyerE, PasquierD, BernadouG, . Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. Eur J Cancer2018;98:38–47.doi:10.1016/j.ejca.2018.04.008
73.
DuY, PahernikS, HadaschikB, . Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. J Neurooncol2016;130:221–8.doi:10.1007/s11060-016-2238-2
74.
MariaB, AntonellaV, MichelaR, . Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy. Ther Adv Med Oncol2016;8:450–9.doi:10.1177/1758834016659825
75.
JohnsonAG, RuizJ, HughesR, . Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget2015;6:18945–55.doi:10.18632/oncotarget.4153
76.
ChenL, DouglassJ, KleinbergL, . Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys2018;100:916–25.doi:10.1016/j.ijrobp.2017.11.041
77.
PikeLRG, BangA, OttP, . Radiation and PD-1 inhibition: favorable outcomes after brain-directed radiation. Radiother Oncol2017;124:98–103.doi:10.1016/j.radonc.2017.06.006
78.
MinasianLM, MotzerRJ, GluckL, . Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol1993;11:1368–75.doi:10.1200/JCO.1993.11.7.1368
79.
QuesadaJR, SwansonDA, GuttermanJU. Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. J Clin Oncol1985;3:1086–92.doi:10.1200/JCO.1985.3.8.1086
80.
RosenbergSA, LotzeMT, YangJC, . Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst1993;85:622–32.doi:10.1093/jnci/85.8.622
81.
FyfeG, FisherRI, RosenbergSA, . Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol1995;13:688–96.doi:10.1200/JCO.1995.13.3.688
82.
ClarkJI, CurtiB, DavisE, . Long-term disease-free survival of patients with metastatic melanoma or renal cell cancer following high dose interleukin-2. Proc Soc Immunother Cancer2017.
83.
DutcherJP, WiernikPH. Interleukin-2 can cure kidney cancer, Letter to editor. The Oncologist2018;23:e107.
84.
McDermottDF, ChengSC, SignorettiS, . The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res2015;21:561–8.doi:10.1158/1078-0432.CCR-14-1520
85.
PayneR, GlennL, HoenH, . Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer2014;2:13.doi:10.1186/2051-1426-2-13
86.
AlvaA, DanielsGA, WongMK, . Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother2016;65:1533–44.doi:10.1007/s00262-016-1910-x
87.
FishmanM, ClarkJI, AlvaA, . Overall survival by clinical risk category for high dose Interleukin-2-treated metastatic renal cell cancer: Data from PROCLAIMTM. J Clin Oncol2018;36(15S:260s.
88.
FolkmanJ, IngberD. Inhibition of angiogenesis. Semin Cancer Biol1992;3:89–96.
89.
MotzerRJ, HutsonTE, TomczakP, . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007;356:115–24.doi:10.1056/NEJMoa065044
90.
EscudierB, EisenT, StadlerWM, . Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol2009;27:3312–8.doi:10.1200/JCO.2008.19.5511
91.
HudesG, CarducciM, TomczakP, . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007;356:2271–81.doi:10.1056/NEJMoa066838
92.
EscudierB, PluzanskaA, KoralewskiP, . AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma. Lancet2007;370:2103–11.
93.
SternbergCN, DavisID, MardiakJ, . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010;28:1061–8.doi:10.1200/JCO.2009.23.9764
94.
RiniBI, EscudierB, TomczakP, . Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet2011;378:1931–9.doi:10.1016/S0140-6736(11)61613-9
95.
MotzerRJ, EscudierB, OudardS, . Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer2010;116:4256–65.doi:10.1002/cncr.25219
96.
ChoueiriTK, EscudierB, PowlesT, . Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol2016;17:917–27.doi:10.1016/S1470-2045(16)30107-3
97.
MotzerRJ, HutsonTE, GlenH, . Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol2015;16:1473–82.doi:10.1016/S1470-2045(15)00290-9
LeachDR, KrummelMF, AllisonJP. Enhancement of antitumor immunity by CTLA-4 blockade. Science1996;271:1734–6.doi:10.1126/science.271.5256.1734
100.
FreemanGJ, LongAJ, IwaiY, . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med2000;192:1027–34.doi:10.1084/jem.192.7.1027
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer2012;12:252–64.doi:10.1038/nrc3239
103.
YangJC, HughesM, KammulaU, . Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother2007;30:825–30.doi:10.1097/CJI.0b013e318156e47e
104.
BrahmerJR, DrakeCG, WollnerI, . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol2010;28:3167–75.doi:10.1200/JCO.2009.26.7609
105.
McGregorBA, FlippotR, ChoueiriT. Evolving role of TKI monotherapy in front line metastatic clear cell RCC. Kidney Cancer Journal2018;16:83–7.
106.
GaoX. Combination immunotherapy and targeted therapy: will new combinations raise the tail of the survival curve?Kidney Cancer Journal2018;16:76–82.
107.
WeinstockM, McDermottD. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol2015;7:365–77.doi:10.1177/1756287215597647
108.
MotzerRJ, TannirNM, McDermottDF, . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med2018;378:1277–90.doi:10.1056/NEJMoa1712126
109.
TannirN, HammersH, AminA. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy. Curr Med Res Opin2018;34:825–31.doi:10.1080/03007995.2018.1423960
AlbigesL, GueganJ, Le FormalA, . MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res2014;20:3411–21.doi:10.1158/1078-0432.CCR-13-2173
112.
MaloufGG, JosephRW, ShahAY, . Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol2017;15:409–18.
113.
MsaouelP, HongAL, MullenEA, . Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer201812.doi:10.1016/j.clgc.2018.09.005
114.
HarrisonMR. The landscape of adjuvant therapy: A controversy in search of a consensus. Kidney Cancer Journal2018;16:88–92.
115.
HaasNB, ManolaJ, UzzoRG, . Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet2016;387:2008–16.doi:10.1016/S0140-6736(16)00559-6
116.
MotzerRJ, HaasNB, DonskovF, . Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol2017;35:3916–23.doi:10.1200/JCO.2017.73.5324
RavaudA, MotzerRJ, PandhaHS, . Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med2016;375:2246–54.doi:10.1056/NEJMoa1611406
119.
HaasNB, ManolaJ, DutcherJP, . Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE Randomized Trial. JAMA Oncol2017;3:1249–52.doi:10.1001/jamaoncol.2017.0076
120.
SternbergCN, DonskovF, HaasNB, . Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma. Clin Cancer Res2018;24:3005–13.doi:10.1158/1078-0432.CCR-17-2652
121.
GeorgeDJ, MartiniJF, StaehlerM, . Immune biomarkers predictive for disease-free survival with adjuvant sunitinib in high-risk locoregional renal cell carcinoma: from randomized phase III S-TRAC Study. Clin Cancer Res2018;24:1554–61.doi:10.1158/1078-0432.CCR-17-2822
122.
MotzerRJ, RavaudA, PatardJJ, . Adjuvant Sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol2018;73:62–8.doi:10.1016/j.eururo.2017.09.008
123.
RiniBI, EscudierB, MartiniJF, . Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase iii trial of adjuvant sunitinib. Clin Cancer Res2018;24:4407–15.doi:10.1158/1078-0432.CCR-18-0323
124.
PrioloC, KhabibullinD, ReznikE, . Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma. Proc Natl Acad Sci U S A2018;115:E6274–82.doi:10.1073/pnas.1710849115
125.
MsaouelP, TannirNM, WalkerCL. A model linking sickle cell hemoglobinopathies and smarcb1 loss in renal medullary carcinoma. Clin Cancer Res2018;24:2044–9.doi:10.1158/1078-0432.CCR-17-3296
126.
MaloufGG, CompératE, YaoH, . Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas. Sci Rep2016;6:30988.doi:10.1038/srep30988
127.
SeoAN, YoonG, RoJY, JyR. Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas. Adv Anat Pathol2017;24:65–77.doi:10.1097/PAP.0000000000000138
128.
LawrieCH, ArmestoM, Fernandez-MercadoM, . Noncoding RNA expression and targeted next-generation sequencing distinguish tubulocystic renal cell carcinoma (tc-rcc) from other renal neoplasms. J Mol Diagn2018;20:34–45.doi:10.1016/j.jmoldx.2017.09.002
129.
KondoT, SasaN, YamadaH, . Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: central pathology results according to the 2016 WHO classification in a multi-institutional study. Pathol Int2018;68:543–9.doi:10.1111/pin.12718
